Boundless Bio, Inc. (BOLD)

9,08 -0,04 (-0,44%) Al cierre: 04:00PM EDT

Boundless Bio, Inc.

9880 Campus Point Drive
Suite 120
San Diego, CA 92121
United States
(858) 766-9912
https://boundlessbio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 72

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Jonathan E. Lim M.D.	Co-Founder & Independent Chairman	N/A	N/A	1972
Mr. Zachary Hornby	CEO, President & Director	721,05k	N/A	1979
Dr. Christian Hassig Ph.D.	Chief Scientific Officer	563,55k	N/A	1973
Dr. Klaus W. Wagner M.D., Ph.D.	Chief Medical Officer	633,08k	N/A	1973
Ms. Jamilu E. Rubin	Chief Financial Officer	N/A	N/A	1964
Ms. Jessica Oien J.D.	Chief Legal Officer & Corporate Secretary	N/A	N/A	1972
Mr. Neil Abdollahian M.B.A., M.S.	Chief Business Officer	N/A	N/A	1973
Mr. Anthony Pinkerton Ph.D.	Senior Vice President of Drug Discovery	N/A	N/A	N/A
Ms. Meredith Wesley	Senior Vice President of Talent & Culture	N/A	N/A	N/A
Dr. Shailaja Kasibhatla Ph.D.	Senior Vice President of Discovery & Translational Development	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

Gobierno corporativo

El ISS Governance QualityScore de Boundless Bio, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.